PortalPublikationenSerum lipopolysaccharide neutralizing capacity in ischemic s...

Serum lipopolysaccharide neutralizing capacity in ischemic stroke

Standard

Serum lipopolysaccharide neutralizing capacity in ischemic stroke. / Leskelä, Jaakko; Pietiäinen, Milla; Safer, Anton; Lehto, Markku; Metso, Jari; Malle, Ernst; Buggle, Florian; Becher, Heiko; Sundvall, Jouko; Grau, Armin J; Pussinen, Pirkko J; Palm, Frederick.

in: PLOS ONE, Jahrgang 15, Nr. 2, 2020, S. e0228806.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Leskelä, J, Pietiäinen, M, Safer, A, Lehto, M, Metso, J, Malle, E, Buggle, F, Becher, H, Sundvall, J, Grau, AJ, Pussinen, PJ & Palm, F 2020, 'Serum lipopolysaccharide neutralizing capacity in ischemic stroke', PLOS ONE, Jg. 15, Nr. 2, S. e0228806. https://doi.org/10.1371/journal.pone.0228806

APA

Leskelä, J., Pietiäinen, M., Safer, A., Lehto, M., Metso, J., Malle, E., Buggle, F., Becher, H., Sundvall, J., Grau, A. J., Pussinen, P. J., & Palm, F. (2020). Serum lipopolysaccharide neutralizing capacity in ischemic stroke. PLOS ONE, 15(2), e0228806. https://doi.org/10.1371/journal.pone.0228806

Vancouver

Leskelä J, Pietiäinen M, Safer A, Lehto M, Metso J, Malle E et al. Serum lipopolysaccharide neutralizing capacity in ischemic stroke. PLOS ONE. 2020;15(2):e0228806. https://doi.org/10.1371/journal.pone.0228806

Bibtex

@article{11704032077d4f6fa0ab1e0740d7859e,
title = "Serum lipopolysaccharide neutralizing capacity in ischemic stroke",
abstract = "INTRODUCTION: Periodontitis is associated with increased serum lipopolysaccharide (LPS) activity, which may be one mechanism linking periodontitis with the risk of cardiovascular diseases. As LPS-carrying proteins including lipoproteins modify LPS-activity, we investigated the determinants of serum LPS-neutralizing capacity (LPS-NC) in ischemic stroke. The association of LPS-NC and Aggregatibacter actinomycetemcomitans, a major microbial biomarker in periodontitis, was also investigated.MATERIALS AND METHODS: The assay to measure LPS-NC was set up by spiking serum samples with E. coli LPS. The LPS-NC, LPS-binding protein (LBP), soluble CD14 (sCD14), lipoprotein profiles, apo(lipoprotein) A-I, apoB, and phospholipid transfer protein (PLTP) activity, were determined in 98 ischemic stroke patients and 100 age- and sex-matched controls. Serum and saliva immune response to A. actinomycetemcomitans, its concentration in saliva, and serotype-distribution were examined.RESULTS: LPS-NC values ranged between 51-83% in the whole population. Although several of the LPS-NC determinants differed significantly between cases and controls (PLTP, sCD14, apoA-I, HDL-cholesterol), the levels did not (p = 0.056). The main determinants of LPS-NC were i) triglycerides (β = -0.68, p<0.001), and ii) HDL cholesterol (0.260, <0.001), LDL cholesterol (-0.265, <0.001), PLTP (-0.196, 0.011), and IgG against A. actinomycetemcomitans (0.174, 0.011). Saliva A. actinomycetemcomitans concentration was higher [log mean (95% CI), 4.39 (2.35-8.19) vs. 10.7 (5.45-21) genomes/ml, p = 0.023) and serotype D more frequent (4 vs. 0%, p = 0.043) in cases than controls. Serotypeablity or serotypes did not, however, relate to the LPS-NC.CONCLUSION: Serum LPS-NC comprised low PLTP-activity, triglyceride and LDL cholesterol concentrations, as well as high HDL cholesterol and IgG against A. actinomycetemcomitans. The present findings let us to conclude that LPS-NC did not associate with stroke.",
author = "Jaakko Leskel{\"a} and Milla Pieti{\"a}inen and Anton Safer and Markku Lehto and Jari Metso and Ernst Malle and Florian Buggle and Heiko Becher and Jouko Sundvall and Grau, {Armin J} and Pussinen, {Pirkko J} and Frederick Palm",
year = "2020",
doi = "10.1371/journal.pone.0228806",
language = "English",
volume = "15",
pages = "e0228806",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - Serum lipopolysaccharide neutralizing capacity in ischemic stroke

AU - Leskelä, Jaakko

AU - Pietiäinen, Milla

AU - Safer, Anton

AU - Lehto, Markku

AU - Metso, Jari

AU - Malle, Ernst

AU - Buggle, Florian

AU - Becher, Heiko

AU - Sundvall, Jouko

AU - Grau, Armin J

AU - Pussinen, Pirkko J

AU - Palm, Frederick

PY - 2020

Y1 - 2020

N2 - INTRODUCTION: Periodontitis is associated with increased serum lipopolysaccharide (LPS) activity, which may be one mechanism linking periodontitis with the risk of cardiovascular diseases. As LPS-carrying proteins including lipoproteins modify LPS-activity, we investigated the determinants of serum LPS-neutralizing capacity (LPS-NC) in ischemic stroke. The association of LPS-NC and Aggregatibacter actinomycetemcomitans, a major microbial biomarker in periodontitis, was also investigated.MATERIALS AND METHODS: The assay to measure LPS-NC was set up by spiking serum samples with E. coli LPS. The LPS-NC, LPS-binding protein (LBP), soluble CD14 (sCD14), lipoprotein profiles, apo(lipoprotein) A-I, apoB, and phospholipid transfer protein (PLTP) activity, were determined in 98 ischemic stroke patients and 100 age- and sex-matched controls. Serum and saliva immune response to A. actinomycetemcomitans, its concentration in saliva, and serotype-distribution were examined.RESULTS: LPS-NC values ranged between 51-83% in the whole population. Although several of the LPS-NC determinants differed significantly between cases and controls (PLTP, sCD14, apoA-I, HDL-cholesterol), the levels did not (p = 0.056). The main determinants of LPS-NC were i) triglycerides (β = -0.68, p<0.001), and ii) HDL cholesterol (0.260, <0.001), LDL cholesterol (-0.265, <0.001), PLTP (-0.196, 0.011), and IgG against A. actinomycetemcomitans (0.174, 0.011). Saliva A. actinomycetemcomitans concentration was higher [log mean (95% CI), 4.39 (2.35-8.19) vs. 10.7 (5.45-21) genomes/ml, p = 0.023) and serotype D more frequent (4 vs. 0%, p = 0.043) in cases than controls. Serotypeablity or serotypes did not, however, relate to the LPS-NC.CONCLUSION: Serum LPS-NC comprised low PLTP-activity, triglyceride and LDL cholesterol concentrations, as well as high HDL cholesterol and IgG against A. actinomycetemcomitans. The present findings let us to conclude that LPS-NC did not associate with stroke.

AB - INTRODUCTION: Periodontitis is associated with increased serum lipopolysaccharide (LPS) activity, which may be one mechanism linking periodontitis with the risk of cardiovascular diseases. As LPS-carrying proteins including lipoproteins modify LPS-activity, we investigated the determinants of serum LPS-neutralizing capacity (LPS-NC) in ischemic stroke. The association of LPS-NC and Aggregatibacter actinomycetemcomitans, a major microbial biomarker in periodontitis, was also investigated.MATERIALS AND METHODS: The assay to measure LPS-NC was set up by spiking serum samples with E. coli LPS. The LPS-NC, LPS-binding protein (LBP), soluble CD14 (sCD14), lipoprotein profiles, apo(lipoprotein) A-I, apoB, and phospholipid transfer protein (PLTP) activity, were determined in 98 ischemic stroke patients and 100 age- and sex-matched controls. Serum and saliva immune response to A. actinomycetemcomitans, its concentration in saliva, and serotype-distribution were examined.RESULTS: LPS-NC values ranged between 51-83% in the whole population. Although several of the LPS-NC determinants differed significantly between cases and controls (PLTP, sCD14, apoA-I, HDL-cholesterol), the levels did not (p = 0.056). The main determinants of LPS-NC were i) triglycerides (β = -0.68, p<0.001), and ii) HDL cholesterol (0.260, <0.001), LDL cholesterol (-0.265, <0.001), PLTP (-0.196, 0.011), and IgG against A. actinomycetemcomitans (0.174, 0.011). Saliva A. actinomycetemcomitans concentration was higher [log mean (95% CI), 4.39 (2.35-8.19) vs. 10.7 (5.45-21) genomes/ml, p = 0.023) and serotype D more frequent (4 vs. 0%, p = 0.043) in cases than controls. Serotypeablity or serotypes did not, however, relate to the LPS-NC.CONCLUSION: Serum LPS-NC comprised low PLTP-activity, triglyceride and LDL cholesterol concentrations, as well as high HDL cholesterol and IgG against A. actinomycetemcomitans. The present findings let us to conclude that LPS-NC did not associate with stroke.

U2 - 10.1371/journal.pone.0228806

DO - 10.1371/journal.pone.0228806

M3 - SCORING: Journal article

C2 - 32084157

VL - 15

SP - e0228806

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 2

ER -